Preparation, physical characterization and pharmacokinetic study of paclitaxel nanocrystals

References

• Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325–7
   PubMed Web of Science ®Google Scholar
• Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 1979;277:665–7
   PubMed Web of Science ®Google Scholar
• Schiff PB, Horwitz SB. Taxol stabilizes microtubes in mouse fibroblast cells. Proc Natl Acad Sci 1980;77:1561–5
   PubMed Web of Science ®Google Scholar
• Spencer CM, Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994;48:794–847
   PubMed Web of Science ®Google Scholar
• Dorr RT. Pharmacology and toxicology of Cremophor EL diluent. Ann Pharmacother 1994;28:S11–14
   PubMed Web of Science ®Google Scholar
• Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263–8
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Eisenhauer EA, Chaudhry V, et al. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993;20:S1–5
   PubMed Web of Science ®Google Scholar
• Stinchcombe TE. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. Nanomedicine (Lond) 2007;2:415–23
   PubMed Web of Science ®Google Scholar
• Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005;23:7785–93
   PubMed Web of Science ®Google Scholar
• Vishnu P, Roy V. Safety and efficacy of nab-paclitaxel in the treatment of patients with breast cancer. Breast Cancer (Auckl) 2011;5:53–65
   PubMedGoogle Scholar
• Xu X, Wang L, Xu HQ, et al. Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer. Asian Pac J Cancer Prev 2013;14:2591–4
   PubMed Web of Science ®Google Scholar
• Lim WT, Tan EH, Toh CK, et al. Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (genexol-PM) in patients with solid tumors. Ann Oncol 2010;21:382–8
   PubMed Web of Science ®Google Scholar
• Wang X, Zhou J, Wang Y, et al. A Phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. Eur J Cancer 2010;46:1474–80
   PubMed Web of Science ®Google Scholar
• Sahu PK, Mishra DK, Jain N, et al. Mannosylated solid lipid nanoparticles for lung-targeted delivery of Paclitaxel. Drug Dev Ind Pharm 2014. [Epub ahead of print]
   Google Scholar
• Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002;235:179–92
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hamad I, Andresen TL, et al. Methylation of the phosphate oxygen moiety of phospholipid-methoxy (polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J 2006;20:2591–3
   PubMed Web of Science ®Google Scholar
• Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 2005;216:106–21
   PubMed Web of Science ®Google Scholar
• Szebeni J, Muggia F, Gabizon A, Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 2011;63:1020–30
   PubMed Web of Science ®Google Scholar
• Junghanns JU, Müller RH. Nanocrystals technology, drug delivery and clinical applications. Int J Nanomedicine 2008;3:295–309
   PubMed Web of Science ®Google Scholar
• Gao L, Liu G, Ma J, et al. Application of drug nanocrystals technologies on oral drug delivery of poorly soluble drugs. Pharm Res 2013;30:307–24
   PubMed Web of Science ®Google Scholar
• Gao L, Zhang D, Chen M. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J Nanopart Res 2008;10:845–62
   Web of Science ®Google Scholar
• Ganta S, Paxton JW, Baguley BC, Garg S. Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int J Pharm 2009;367:179–86
   PubMed Web of Science ®Google Scholar
• Shegokar R, Müller RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm 2010;399:129–39
   PubMed Web of Science ®Google Scholar
• Liu F, Park JY, Zhang Y, et al. Targeted cancer therapy with novel high drug-loading nanocrystals. J Pharm Sci 2010;99:3542–51
   PubMed Web of Science ®Google Scholar
• Wang Y, Jiang G, Qiu T, Ding F. Preparation and evaluation of paclitaxel-loaded nanoparticle incorporated with galactose-carrying polymer for hepatocyte targeted delivery. Drug Dev Ind Pharm 2012;38:1039–46
   PubMed Web of Science ®Google Scholar
• Hirun N, Sangfai T, Tantishaiyakul V. Characterization of freeze-dried gallic acid/xyloglucan. Drug Dev Ind Pharm 2013. [Epub ahead of print]
   Google Scholar
• Wang Y, Li X, Wang L, et al. Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. Int J Nanomedicine 2011;6:1497–507
   PubMed Web of Science ®Google Scholar
• Zhu Z, Li Y, Li X, et al. Paclitaxel-loaded poly (N-vinylpyrrolidone)-b-poly(epsilon-caprolactone) nanoparticles: preparation and antitumor activity in vivo. J Control Release 2010;142:438–46
   PubMed Web of Science ®Google Scholar
• Belete A, Metz H, Mueller T, Maeder K. Benchtop MRI for pharmacokinetic evaluation of two aqueous-based nano-scaled formulations of oleic acid stabilized magnetite nanocrystals. Drug Dev Ind Pharm 2013. [Epub ahead of print]
   Google Scholar
• Nagarwal RC, Kumar R, Dhanawat M, et al. Nanocrystal technology in the delivery of poorly solubility drugs: an overview. Curr Drug Deliv 2011;8:398–406
   PubMed Web of Science ®Google Scholar
• Müller RH, Jacobs C. Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int J Pharm 2002;237:151–61
   PubMed Web of Science ®Google Scholar
• Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm 2008;69:1–9
   PubMed Web of Science ®Google Scholar